The activation of JAK/STAT signaling and the benefits brought about by Jak inhibitors may reflect the effects that the JAK/STAT pathway has on different factors related to DKD, and targeting this signaling is promising for the treatment of DKD. The gene discussed is SOAT1; the disease is diabetic kidney disease.